A commercial stage, pharmaceutical company delivering innovative speciality pharmaceuticals that address patients’ unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders.
Accrufer® / Feraccru®
Our lead product is approved for the treatment of iron deficiency with or without anaemia in adults in the United States, European Union, UK and Switzerland and has exclusive IP rights until the mid 2030s.
In Europe the product is marketed as Feraccru® with commercialisation led by Norgine BV. In the USA – where the product also benefits from NCE exclusivity until 2020 – it is marketed as Accrufer®.
We also have an exclusive licence agreement with ASK Pharm, who will lead the development and commercialisation in China.Read more